Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

被引：42
|
作者：
Carlin, Aaron F. [1 ]
Clark, Alex E. [1 ]
Chaillon, Antoine [1 ]
Garretson, Aaron F. [1 ]
Bray, William [2 ]
Porrachia, Magali [1 ]
Santos, AsherLev T. [3 ]
Rana, Tariq M. [4 ]
Smith, Davey M. [1 ,5 ]
机构：
[1] Univ Calif San Diego, Sch Med, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA
[3] Calif State Univ San Marcos, Coll Educ Hlth & Human Serv, Dept Publ Hlth, San Marcos, CA USA
[4] Univ Calif San Diego, UCSD Ctr AIDS Res, Inst Genom Med, Dept Pediat Program Immunol,Div Genet, La Jolla, CA 92093 USA
[5] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期
关键词：
COVID-19; treatment rebound; recrudescence; nirmatrelvir; Omicron;
D O I：
10.1093/cid/ciac496
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.
引用
收藏
页码：E530 / E532
页数：3
相关论文
共 50 条
  • [1] Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment
    Epling, Brian P.
    Rocco, Joseph M.
    Boswell, Kristin L.
    Laidlaw, Elizabeth
    Galindo, Frances
    Kellogg, Anela
    Das, Sanchita
    Roder, Allison
    Ghedin, Elodie
    Kreitman, Allie
    Dewar, Robin L.
    Kelly, Sophie E. M.
    Kalish, Heather
    Rehman, Tauseef
    Highbarger, Jeroen
    Rupert, Adam
    Kocher, Gregory
    Holbrook, Michael R.
    Lisco, Andrea
    Manion, Maura
    Koup, Richard A.
    Sereti, Irini
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 573 - 581
  • [2] Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)
    Boucau, Julie
    Uddin, Rockib
    Marino, Caitlin
    Regan, James
    Flynn, James P.
    Choudhary, Manish C.
    Chen, Geoffrey
    Stuckwisch, Ashley M.
    Mathews, Josh
    Liew, May Y.
    Singh, Arshdeep
    Reynolds, Zahra
    Iyer, Surabhi L.
    Chamberlin, Grace C.
    Vyas, Tammy D.
    Vyas, Jatin M.
    Turbett, Sarah E.
    Li, Jonathan Z.
    Lemieux, Jacob E.
    Barczak, Amy K.
    Siedner, Mark J.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E526 - E529
  • [3] Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment
    Lai, Chih-Cheng
    Hsueh, Po-Ren
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [4] A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019
    Haslam, Alyson
    Prasad, Vinay
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [5] Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
    Marchetti, Giulia
    Rovito, Roberta
    Bono, Valeria
    Bonara, Paola
    Bai, Francesca
    Monforte, Antonella d'Arminio
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (05) : 660 - 662
  • [6] Complexity Interactions Between Nirmatrelvir/Ritonavir and Voriconazole in Patients With Coronavirus Disease 2019
    Wang, Peile
    Xing, Han
    Zhang, Xiaojian
    Yang, Jing
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (12) : 2209 - 2210
  • [7] Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs
    Saravolatz, Louis D.
    Depcinski, Shawn
    Sharma, Mamta
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (01) : 165 - 171
  • [8] Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons
    Ranganath, Nischal
    O'Horo, John C.
    Challener, Douglas W.
    Tulledge-Scheitel, Sidna M.
    Pike, Marsha L.
    O'Brien, R. Michael
    Razonable, Raymund R.
    Shah, Aditya
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E537 - E539
  • [9] Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study
    Park, Jin Ju
    Lee, Jacob
    Seo, Yu Bin
    Na, Sun Hee
    INFECTION AND CHEMOTHERAPY, 2022, 54 (04): : 757 - 764
  • [10] Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019
    Hiremath, Swapnil
    Blake, Peter G.
    Yeung, Angie
    McGuinty, Michaeline
    Thomas, Doneal
    Ip, Jane
    Brown, Pierre Antoine
    Pandes, Michael
    Burke, Andrew
    Sohail, Qazi Zain
    To, Karen
    Blackwell, Lindsay
    Oliver, Matthew
    Jain, Arsh K.
    Chagla, Zain
    Cooper, Rebecca
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (04): : 485 - 490
12345